Loading…
Lobbying Spend
—
Filings
22
Firms Hired
1
Active Period
2021–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Consolidated Appropriations Act, 2023
2022 · fourth_quarter · Firm: COVINGTON & BURLING LLP
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667); Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (H.R.6833); Consolidated Appropriations Act, 2023 (H.R. 2617).
Client expense: — · Firm income: $30,000
Matched citations: H.R. 2617
Consolidated Appropriations Act, 2023
2022 · fourth_quarter · Firm: COVINGTON & BURLING LLP
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667); Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (H.R.6833); Consolidated Appropriations Act, 2023 (H.R. 2617).
Client expense: — · Firm income: $30,000
Matched citations: H.R. 2617
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667); Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (H.R.6833); Consolidated Appropriations Act, 2023 (H.R. 2617).
Client expense: — · Firm income: $30,000
Matched citations: H.R. 6000
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667); Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (H.R.6833); Consolidated Appropriations Act, 2023 (H.R. 2617).
Client expense: — · Firm income: $30,000
Matched citations: H.R. 6000
Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
2022 · fourth_quarter · Firm: COVINGTON & BURLING LLP
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667); Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (H.R.6833); Consolidated Appropriations Act, 2023 (H.R. 2617).
Client expense: — · Firm income: $30,000
Matched citations: H.R.6833
Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
2022 · fourth_quarter · Firm: COVINGTON & BURLING LLP
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667); Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (H.R.6833); Consolidated Appropriations Act, 2023 (H.R. 2617).
Client expense: — · Firm income: $30,000
Matched citations: H.R.6833
Food and Drug Amendments of 2022
2022 · fourth_quarter · Firm: COVINGTON & BURLING LLP
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667); Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (H.R.6833); Consolidated Appropriations Act, 2023 (H.R. 2617).
Client expense: — · Firm income: $30,000
Matched citations: H.R. 7667
Food and Drug Amendments of 2022
2022 · fourth_quarter · Firm: COVINGTON & BURLING LLP
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667); Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (H.R.6833); Consolidated Appropriations Act, 2023 (H.R. 2617).
Client expense: — · Firm income: $30,000
Matched citations: H.R. 7667
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667); Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (H.R.6833); Consolidated Appropriations Act, 2023 (H.R. 2617).
Client expense: — · Firm income: $30,000
Matched citations: S. 3799
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667); Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (H.R.6833); Consolidated Appropriations Act, 2023 (H.R. 2617).
Client expense: — · Firm income: $30,000
Matched citations: S. 3799
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667); Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (H.R.6833); Consolidated Appropriations Act, 2023 (H.R. 2617).
Client expense: — · Firm income: $30,000
Matched citations: S. 4348
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667); Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (H.R.6833); Consolidated Appropriations Act, 2023 (H.R. 2617).
Client expense: — · Firm income: $30,000
Matched citations: S. 4348
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667); Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (H.R.6833).
Client expense: — · Firm income: $50,000
Matched citations: H.R. 6000
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667); Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (H.R.6833).
Client expense: — · Firm income: $50,000
Matched citations: H.R. 6000
Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
2022 · third_quarter · Firm: COVINGTON & BURLING LLP
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667); Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (H.R.6833).
Client expense: — · Firm income: $50,000
Matched citations: H.R.6833
Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
2022 · third_quarter · Firm: COVINGTON & BURLING LLP
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667); Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (H.R.6833).
Client expense: — · Firm income: $50,000
Matched citations: H.R.6833
Food and Drug Amendments of 2022
2022 · third_quarter · Firm: COVINGTON & BURLING LLP
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667); Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (H.R.6833).
Client expense: — · Firm income: $50,000
Matched citations: H.R. 7667
Food and Drug Amendments of 2022
2022 · third_quarter · Firm: COVINGTON & BURLING LLP
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667); Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (H.R.6833).
Client expense: — · Firm income: $50,000
Matched citations: H.R. 7667
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667); Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (H.R.6833).
Client expense: — · Firm income: $50,000
Matched citations: S. 3799
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667); Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (H.R.6833).
Client expense: — · Firm income: $50,000
Matched citations: S. 3799
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667); Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (H.R.6833).
Client expense: — · Firm income: $50,000
Matched citations: S. 4348
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667); Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (H.R.6833).
Client expense: — · Firm income: $50,000
Matched citations: S. 4348
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667).
Client expense: — · Firm income: $90,000
Matched citations: H.R. 6000
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667).
Client expense: — · Firm income: $90,000
Matched citations: H.R. 6000
Food and Drug Amendments of 2022
2022 · second_quarter · Firm: COVINGTON & BURLING LLP
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667).
Client expense: — · Firm income: $90,000
Matched citations: H.R. 7667
Source: Senate LDA